Investments, Funding & Disinvestment

The new facility is designed to address the growing prevalence of sleep disorders, which remain among the most underdiagnosed health conditions despite their serious impact on long-term wellbeing.

The new capability strengthens Abu Dhabi’s broader preventive healthcare strategy by equipping public and private sector institutions with faster access to highly accurate toxicology data.

The new office will host Insulet’s full regional leadership and operational teams, serving as the company’s central hub for clinical collaboration, partner development, market access initiatives, and talent investment across the region.

This year’s event also builds on commitments outlined in the Durban Promise, adopted during CPHIA 2025, which calls for stronger governance, increased investment in primary healthcare systems, and greater regional collaboration to achieve health sovereignty.

The acquisition builds on an established collaboration between Roche and PathAI that began in 2021 and expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms.

The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.

Catalyst Pharmaceuticals, listed on Nasdaq in 2006, has evolved into a focused rare disease company with strong commercial momentum.

Neuralink’s clinical programme has recorded notable early milestones, including reports that its first human participant successfully operated a computer and typed using neural signals alone.

The initiative will leverage the UAE–India healthcare corridor to expand access to gene therapies for high-need populations and strengthen cross-border biomedical collaboration.

Under the agreement, Madrigal will take over the development, manufacturing, and commercialisation of Arrowhead’s investigational therapy, ARO-PNPLA3.